Literature DB >> 8500289

Detection of substance use disorders in severely mentally ill patients.

R E Drake1, A I Alterman, S R Rosenberg.   

Abstract

Severe mental illness is frequently complicated by substance use disorder. Approximately half of the severely mentally ill patients treated in acute care psychiatric settings have abused one or more of these substances. Despite the high rate of comorbidity, substance use disorders are generally not detected in acute care psychiatric settings, leading to incorrect diagnoses and ineffective treatments. The reasons for nondetection are complex, and research is needed to refine instruments and procedures for the detection of substance abuse in the severely mentally ill population. Nevertheless, clinicians can make better use of existing techniques of multimodal assessment to increase significantly the rate of accurate detection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500289     DOI: 10.1007/BF00756343

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  69 in total

1.  THE MULTIPLE READMISSION PSYCHIATRIC PATIENT.

Authors:  A D POKORNY
Journal:  Psychiatr Q       Date:  1965-01

2.  Substance use in young adults with schizophrenic disorders.

Authors:  M A Test; L S Wallisch; D J Allness; K Ripp
Journal:  Schizophr Bull       Date:  1989       Impact factor: 9.306

3.  A comparison of a commercial microdiffusion method and gas chromatography for ethanol analysis.

Authors:  R A Cox; J A Crifasi
Journal:  J Anal Toxicol       Date:  1990 Jul-Aug       Impact factor: 3.367

4.  Covert drug abuse among voluntary hospitalized psychiatric patients.

Authors:  A G Blumberg; M Cohen; A M Heaton; D F Klein
Journal:  JAMA       Date:  1971-09-20       Impact factor: 56.272

5.  Amphetamine abuse amongst psychiatric in-patients. The use of gas chromatography.

Authors:  A E Robinson; S N Wolkind
Journal:  Br J Psychiatry       Date:  1970-06       Impact factor: 9.319

6.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

Authors:  L N Robins; J E Helzer; J Croughan; K S Ratcliff
Journal:  Arch Gen Psychiatry       Date:  1981-04

7.  Reliability of alcohol use indices. The Lifetime Drinking History and the MAST.

Authors:  H A Skinner; W J Sheu
Journal:  J Stud Alcohol       Date:  1982-11

Review 8.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses.

Authors:  J A Lieberman; B J Kinon; A D Loebel
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

9.  Role of the laboratory in the evaluation of suspected drug abuse.

Authors:  M S Gold; C A Dackis
Journal:  J Clin Psychiatry       Date:  1986-01       Impact factor: 4.384

10.  Recent psychostimulant use in hospitalized schizophrenics.

Authors:  M L Richard; B I Liskow; P J Perry
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384

View more
  17 in total

1.  Remote "hovering" with individuals with psychotic disorders and substance use: feasibility, engagement, and therapeutic alliance with a text-messaging mobile interventionist.

Authors:  Dror Ben-Zeev; Susan M Kaiser; Izabela Krzos
Journal:  J Dual Diagn       Date:  2014

Review 2.  Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review.

Authors:  Giuseppe Carrà; Sonia Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-13       Impact factor: 4.328

Review 3.  Organizational guidelines for dual disorders programs.

Authors:  C C Mercer; K T Mueser; R E Drake
Journal:  Psychiatr Q       Date:  1998

4.  Impact of assertive community treatment on homeless persons with co-occurring severe psychiatric and substance use disorders.

Authors:  N Meisler; L Blankertz; A B Santos; C McKay
Journal:  Community Ment Health J       Date:  1997-04

5.  The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).

Authors:  Giuseppe Carrà; Sonia Johnson; Paul Bebbington; Matthias C Angermeyer; Dirk Heider; Traolach Brugha; Jean-Michel Azorin; Mondher Toumi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

6.  Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders?

Authors:  D A Zanis; A T McLellan; S Corse
Journal:  Community Ment Health J       Date:  1997-06

7.  The role of inpatient care for patients with co-occurring severe mental disorder and substance use disorder.

Authors:  R E Drake; D L Noordsy
Journal:  Community Ment Health J       Date:  1995-06

8.  Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia.

Authors:  Sarah L Desmarais; Richard A Van Dorn; Brian G Sellers; M Scott Young; Marvin S Swartz
Journal:  Psychol Addict Behav       Date:  2012-12-31

9.  Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.

Authors:  Mary F Brunette; Robert E Drake; Haiyi Xie; Gregory J McHugo; Alan I Green
Journal:  Schizophr Bull       Date:  2006-06-16       Impact factor: 9.306

10.  Gender differences in homeless persons with schizophrenia and substance abuse.

Authors:  M Brunette; R E Drake
Journal:  Community Ment Health J       Date:  1998-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.